UCB sketches grand plans for new headquarters as it grabs Eli Lilly's abandoned neuro R&D campus
Belgium’s UCB is set to invest more than £1 billion ($1.29 billion) in the UK over the next five years — starting with a brand new headquarters built on a campus it’s acquiring from Eli Lilly.
The company has “state-of-the-art refurbishment” planned for the 47-acre facility in Windlesham, Surrey, before it relocates from the current UK home in Slough, Berkshire. For an idea of its scale, UCB boasted that its new campus used to be Lilly’s second-largest research site worldwide.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
